- Home
- ATXS vs GBLI Comparison
ATXS vs GBLI Comparison
Compare ATXS & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- GBLI
- Stock Information
- Founded
- ATXS 2008
- GBLI 2016
- Country
- ATXS United States
- GBLI United States
- Employees
- ATXS N/A
- GBLI N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- ATXS Health Care
- GBLI Finance
- Exchange
- ATXS Nasdaq
- GBLI Nasdaq
- Market Cap
- ATXS 516.4M
- GBLI 476.1M
- IPO Year
- ATXS 2015
- GBLI 2003
- Fundamental
- Price
- ATXS $7.50
- GBLI $35.44
- Analyst Decision
- ATXS Strong Buy
- GBLI
- Analyst Count
- ATXS 5
- GBLI 0
- Target Price
- ATXS $25.60
- GBLI N/A
- AVG Volume (30 Days)
- ATXS 368.6K
- GBLI 5.1K
- Earning Date
- ATXS 03-03-2025
- GBLI 03-12-2025
- Dividend Yield
- ATXS N/A
- GBLI 4.03%
- EPS Growth
- ATXS N/A
- GBLI 90.04
- EPS
- ATXS N/A
- GBLI 2.92
- Revenue
- ATXS N/A
- GBLI $442,500,000.00
- Revenue This Year
- ATXS N/A
- GBLI N/A
- Revenue Next Year
- ATXS N/A
- GBLI $8.39
- P/E Ratio
- ATXS N/A
- GBLI $11.91
- Revenue Growth
- ATXS N/A
- GBLI N/A
- 52 Week Low
- ATXS $6.96
- GBLI $27.47
- 52 Week High
- ATXS $16.90
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- ATXS 29.58
- GBLI 49.88
- Support Level
- ATXS $7.29
- GBLI $33.12
- Resistance Level
- ATXS $7.95
- GBLI $36.51
- Average True Range (ATR)
- ATXS 0.42
- GBLI 0.73
- MACD
- ATXS -0.08
- GBLI -0.17
- Stochastic Oscillator
- ATXS 15.25
- GBLI 62.70
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.